Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;36(6):1012-6.
doi: 10.1007/s11064-011-0442-1. Epub 2011 Mar 12.

The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis

Elżbieta Miller  1 , Małgorzata Mrowicka, Joanna Saluk-Juszczak, Majsterek Ireneusz
Affiliations

The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis

Elżbieta Miller et al. Neurochem Res. 2011 Jun.

Abstract

Oxidative stress leads to lipid peroxidation and may contribute to the pathogenesis of lesions in multiple sclerosis (MS), an autoimmune disease characterized by inflammatory as well as degenerative phenomena. Isoprostanes are prostaglandin-like compounds which are formed by free radical catalysed peroxidation of arachidonic acid esterified in membrane phospholipids. They are a new class of sensitive specific markers for in vivo lipid peroxidation. In this study 26 patients (15 females and 11 males; mean age 48.2 ± 15.2 year; mean disease duration 10.0 ± 6.5 year) with secondary progressive MS (SPMS) and 12 healthy controls were enrolled. In patients with multiple sclerosis the lipid peroxidation as the level of urine isoprostanes and the level of thiobarbituric acid reactive species (TBARS) in plasma were estimated. Moreover, we estimated the total antioxidative status (TAS) in plasma. It was found that the urine isoprostanes level was over 6-fold elevated in patients with SPMS than in control (P < 0.001). In SPMS patients TBARS level was also statistically higher than in controls (P < 0.01). However, we did not observed any difference of TAS level in serum between SPMS patients and controls (P > 0.05). In patients with SPMS the lipid peroxidation and oxidative stress measured as the increased level of isoprostanes was observed. Thus, we suggest that the level of isoprostanes may be used as non-invasive marker for a determination of oxidative stress what in turn, together with clinical symptoms, may determine an specific antioxidative therapy in SPMS patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Isoprostanes (8-EPI) in urine of secondary progressive multiple sclerosis (SPMS) patients and controls
Fig. 2
Fig. 2
TBARS in plasma of secondary progressive multiple sclerosis (SPMS) patients and controls
Fig. 3
Fig. 3
Total antioxidative status (TAS) in plasma of secondary progressive multiple sclerosis (SPMS) patients and controls
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004;127:1463–1478. doi: 10.1093/brain/awh176. - DOI - PubMed
    1. Pokryszko-Dragan A, Gruszka E, Bilińska M. Secondary progressive multiple sclerosis-clinical course and potential predictive factors. Neurol Neurochir Pol. 2008;42:6–11. - PubMed
    1. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis. The need for the effective antioxidant therapy. J Neurol. 2004;25:261–268. - PubMed
    1. Gonsette R. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler. 2008;14:22–34. doi: 10.1177/1352458507080111. - DOI - PubMed
    1. Miller E (2011) Multiple sclerosis. In: Shamim I Ahmad. Neurodegenerative diseases. Springer Lands Bioscience. [in press]
  NODES
twitter 2